Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics

Spark Therapeutics logoSpark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONCE
  • CUSIP:
Key Metrics:
  • Previous Close: $60.48
  • 50 Day Moving Average: $60.96
  • 200 Day Moving Average: $57.06
  • 52-Week Range: $28.38 - $65.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -24.37
  • P/E Growth: 0.00
  • Market Cap: $1.84B
  • Outstanding Shares: 30,773,000
  • Beta: 3.51
Profitability:
  • Net Margins: -441.05%
  • Return on Equity: -28.28%
  • Return on Assets: -25.39%
Debt:
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Additional Links:
Companies Related to Spark Therapeutics:

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $64.50 (7.61% upside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017Jefferies Group LLCSet Price TargetHold$59.00View Rating Details
2/22/2017Cowen and CompanySet Price TargetBuy$75.00View Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00View Rating Details
2/23/2017Cantor FitzgeraldReiterated RatingBuy$94.00View Rating Details
2/23/2017Stifel NicolausBoost Price TargetBuy$73.00 -> $76.00View Rating Details
2/22/2017WedbushReiterated RatingUnderperform$28.00View Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00View Rating Details
12/20/2016BMO Capital MarketsInitiated CoverageOutperform$69.00View Rating Details
12/6/2016Chardan CapitalReiterated RatingNeutralView Rating Details
7/12/2016Royal Bank of CanadaInitiated CoverageOutperform$70.00View Rating Details
6/21/2016SunTrust Banks, Inc.Boost Price TargetBuy$64.00 -> $72.00View Rating Details
4/12/2016Evercore ISIInitiated CoverageBuy$37.00View Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Neutral$44.00View Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldView Rating Details
10/11/2015Roth CapitalReiterated RatingBuyView Rating Details
5/6/2015Credit Suisse GroupInitiated CoverageOutperform$76.00View Rating Details
2/25/2015Sanford C. BernsteinInitiated CoverageMarket PerformView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Spark Therapeutics (NASDAQ:ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
2/22/2017Q416($1.12)($1.21)$2.64 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)ViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
Current Year EPS Consensus Estimate: $-5.26 EPS
Next Year EPS Consensus Estimate: $-2.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.04)($0.80)($0.88)
Q2 20164($0.97)($0.83)($0.88)
Q3 20164($1.01)($0.95)($0.97)
Q4 20165($1.18)($0.99)($1.05)
Q1 20174($1.75)($1.32)($1.44)
Q2 20174($1.82)($1.24)($1.45)
Q3 20174($1.85)($1.23)($1.47)
Q4 20174($1.87)($1.27)($1.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 83.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
DateHeadline
News IconSpark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Hold" from the Analysts (NASDAQ:ONCE)
latribunadecanarias.com - February 24 at 8:07 PM
News IconThe Spark Therapeutics, Inc. (ONCE) Given Average Rating of "Hold" by Brokerages (NASDAQ:ONCE)
prensariotiretail.com - February 24 at 8:07 PM
capitalcube.com logoSpark Therapeutics, Inc. :ONCE-US: Earnings Analysis: 2016 By the Numbers : February 24, 2017 (NASDAQ:ONCE)
www.capitalcube.com - February 24 at 8:07 PM
News IconSpark Therapeutics, Inc. (ONCE) Issues FY16 Earnings Guidance (NASDAQ:ONCE)
mundoaguaysaneamiento.net - February 24 at 8:47 AM
biz.yahoo.com logoSpark Therapeutics Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:ONCE)
us.rd.yahoo.com - February 24 at 8:47 AM
News IconWith A Strong Pipeline, Plenty Of Catalysts Lie Ahead For Spark Therapeutics (ONCE) (NASDAQ:ONCE)
www.economiccalendar.com - February 23 at 7:06 PM
us.rd.yahoo.com logo7:34 am Spark Therapeutics reports FY16 results (NASDAQ:ONCE)
us.rd.yahoo.com - February 23 at 12:10 AM
finance.yahoo.com logoEdited Transcript of ONCE earnings conference call or presentation 22-Feb-17 1:30pm GMT (NASDAQ:ONCE)
finance.yahoo.com - February 23 at 12:10 AM
News IconStock On Watchlist: Spark Therapeutics, Inc. (NASDAQ:ONCE) Price Target Watch - Rockville Register (NASDAQ:ONCE)
rockvilleregister.com - February 22 at 7:09 PM
News IconStock Levels in Review: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Searcy News (NASDAQ:ONCE)
searcysentinel.com - February 22 at 7:09 PM
seekingalpha.com logoSpark Therapeutics, Inc.'s (ONCE) CEO Jeffrey Marrazzo on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:ONCE)
seekingalpha.com - February 22 at 7:09 PM
bizjournals.com logoWhy Spark's CEO says 2017 may be a 'historic year' for his gene therapy company (NASDAQ:ONCE)
www.bizjournals.com - February 22 at 7:09 PM
marketexclusive.com logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Results of Operations and Financial Condition (NASDAQ:ONCE)
marketexclusive.com - February 22 at 9:06 AM
us.rd.yahoo.com logoSpark Therapeutics Reports 2016 Financial Results and Business Highlights (NASDAQ:ONCE)
us.rd.yahoo.com - February 22 at 9:06 AM
biz.yahoo.com logoSPARK THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:ONCE)
biz.yahoo.com - February 22 at 9:06 AM
News IconEPS Of Spark Therapeutics, Inc. (NASDAQ:ONCE) At $-1.13 - Stock Observer (NASDAQ:ONCE)
www.thestockobserver.com - February 17 at 4:42 PM
News IconSell-side Consensus Sees Spark Therapeutics, Inc. (NASDAQ:ONCE) Going Where Near-Term? - Aiken Advocate (NASDAQ:ONCE)
aikenadvocate.com - February 16 at 6:35 PM
finance.yahoo.com logoSpark Therapeutics to Host Conference Call on Wednesday, Feb. 22 at 8:30 a.m. to Discuss 2016 Results (NASDAQ:ONCE)
finance.yahoo.com - February 16 at 6:35 PM
News IconShares in Review: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Midway Monitor (NASDAQ:ONCE)
midwaymonitor.com - February 15 at 3:40 AM
realistinvestor.com logoSpark Therapeutics, Inc. (NASDAQ:ONCE) EPS Projection At $-1.1767 - RealistInvestor.com (NASDAQ:ONCE)
www.realistinvestor.com - February 13 at 8:20 PM
News IconSpark Therapeutics Inc (ONCE) is Initiated by Leerink Partners to “Outperform” - Highland Mirror (NASDAQ:ONCE)
www.highlandmirror.com - February 11 at 7:06 PM
finance.yahoo.com logoCoverage initiated on Spark Therapeutics by Leerink Partners (NASDAQ:ONCE)
finance.yahoo.com - February 9 at 8:08 PM
News IconNews Impact Score Of Spark Therapeutics, Inc. (NASDAQ:ONCE) At ... - Stock Observer (NASDAQ:ONCE)
www.thestockobserver.com - February 9 at 1:01 AM
nasdaq.com logoCommit To Buy Spark Therapeutics At $55, Earn 18.5% Annualized Using Options (NASDAQ:ONCE)
www.nasdaq.com - February 8 at 7:59 PM
News IconTrading Review: Narrowing in on Shares of Spark Therapeutics Inc. (ONCE) - Davidson Register (NASDAQ:ONCE)
davidsonregister.com - February 8 at 1:10 AM
News IconTracking the Numbers for Spark Therapeutics, Inc. (NASDAQ:ONCE) - The Tribune (NASDAQ:ONCE)
lakecitytribune.com - January 30 at 8:44 AM
News IconSpark Therapeutics, Inc. (NASDAQ:ONCE) Quarterly EPS Projection At $-1.13 - Stock Observer (NASDAQ:ONCE)
www.thestockobserver.com - January 30 at 12:32 AM
finance.yahoo.com logoSpark Therapeutics to Participate in Multiple February Conferences (NASDAQ:ONCE)
finance.yahoo.com - January 27 at 12:10 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Aiken Advocate (NASDAQ:ONCE)
aikenadvocate.com - January 25 at 11:16 PM
News IconTechnical Trading Review on Shares of Spark Therapeutics Inc. (ONCE) - Market Point (NASDAQ:ONCE)
mtptnews.com - January 25 at 11:16 PM
News IconValue Focus: Following the Numbers for Spark Therapeutics, Inc. (NASDAQ:ONCE) - The Tribune (NASDAQ:ONCE)
lakecitytribune.com - January 25 at 5:50 AM
News IconNews Impact Score Of Spark Therapeutics, Inc. (NASDAQ:ONCE ... - Stock Observer (NASDAQ:ONCE)
www.thestockobserver.com - January 19 at 11:41 PM
capitalcube.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : January 18, 2017 (NASDAQ:ONCE)
www.capitalcube.com - January 18 at 7:39 PM
News IconStock Worth Watching: Spark Therapeutics Inc Stock Is Rising Now - Fair View Times (NASDAQ:ONCE)
fairviewtimes.com - January 13 at 12:42 AM
News IconWill The Needle Move For Spark Therapeutics, Inc. (NASDAQ:ONCE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ONCE)
wsbeacon.com - January 13 at 12:42 AM
News IconStock Getting Tripped Up In Session: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Wall Street Beacon (NASDAQ:ONCE)
wsbeacon.com - January 12 at 12:42 AM
News IconStock Reaching Most Volatile List Today: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Wall Street Beacon (NASDAQ:ONCE)
wsbeacon.com - January 12 at 12:42 AM
us.rd.yahoo.com logoSpark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy (NASDAQ:ONCE)
us.rd.yahoo.com - January 10 at 12:43 AM
realistinvestor.com logoSpark Therapeutics, Inc. (NASDAQ:ONCE) EPS Estimate At $-1.16 - RealistInvestor.com (NASDAQ:ONCE)
www.realistinvestor.com - January 9 at 7:43 PM
News IconSpark Therapeutics, Inc. (NASDAQ:ONCE) EPS At $-1.13 - Stock Observer (NASDAQ:ONCE)
www.thestockobserver.com - January 7 at 5:49 AM
benzinga.com logoSpark Gets A Check From Pfizer And A Downgrade From ... - Benzinga - Benzinga (NASDAQ:ONCE)
www.benzinga.com - January 6 at 4:45 AM
capitalcube.com logoSpark Therapeutics, Inc. – Value Analysis (NASDAQ:ONCE) : January 5, 2017 (NASDAQ:ONCE)
www.capitalcube.com - January 5 at 11:44 PM
finance.yahoo.com logoSpark Gets A Check From Pfizer And A Downgrade From Vetr (NASDAQ:ONCE)
finance.yahoo.com - January 5 at 11:44 PM
nasdaq.com logoSpark Therapeutics Announces Milestone Payment From Pfizer - Quick Facts (NASDAQ:ONCE)
www.nasdaq.com - January 5 at 12:52 AM
News IconSpark Therapeutics Announces Milestone Payment From Pfizer (NASDAQ:ONCE)
www.bioportfolio.com - January 4 at 7:49 PM
streetinsider.com logoSpark Therapeutics (ONCE) Receives $15M Milestone Payment from Pfizer (PFE) for Progress in Hemophilia B Gene Therapy Program (NASDAQ:ONCE)
www.streetinsider.com - January 4 at 7:49 PM
finance.yahoo.com logoSpark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program (NASDAQ:ONCE)
finance.yahoo.com - January 4 at 7:49 PM
finance.yahoo.com logo7:32 am Spark Therapeutics announces $15 mln milestone payment from Pfizer (PFE (NASDAQ:ONCE)
finance.yahoo.com - January 4 at 7:49 PM
capitalcube.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : January 4, 2017 (NASDAQ:ONCE)
www.capitalcube.com - January 4 at 7:49 PM
bizjournals.com logoSpark reels in second $15M payment from Pfizer (NASDAQ:ONCE)
www.bizjournals.com - January 4 at 7:49 PM

Social

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

13 equities research analysts have issued 12-month price targets for Spark Therapeutics' shares. Their predictions range from $28.00 to $94.00. On average, they expect Spark Therapeutics' share price to reach $64.50 in the next year.

When will Spark Therapeutics announce their earnings?

Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)

  • Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)
  • According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (1/14/2017)

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Federated Investors Inc. PA (4.46%), State Street Corp (2.93%), Janus Capital Management LLC (1.23%), Bain Capital Public Equity Management LLC (1.07%) and Deerfield Management Co. (0.92%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Deerfield Management Co., Bain Capital Public Equity Management LLC, Janus Capital Management LLC and AQR Capital Management LLC. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, State Street Corp, Marshall Wace LLP, Guggenheim Capital LLC, FMR LLC, Russell Investments Group Ltd., Pacad Investment Ltd. and Fred Alger Management Inc..

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Spark Therapeutics stock cost?

One share of Spark Therapeutics stock can currently be purchased for approximately $59.94.

Spark Therapeutics (NASDAQ:ONCE) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Earnings History Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Dividend History Chart

Dividend Payments by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Last Updated on 2/25/2017 by MarketBeat.com Staff